Model Can Predict, Stratify Liver Cancer Risk in Noncirrhotic Chronic Hep B

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, Sept. 17, 2024 -- A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with chronic hepatitis B (CHB), according to a study published online Sept. 17 in the Annals of Internal Medicine.

Gi-Ae Kim, M.D., Ph.D., from Kyung Hee University Hospital in Seoul, South Korea, and colleagues developed and externally validated a prognostic model for HCC risk in noncirrhotic adult patients with CHB, without notable alanine aminotransferase (ALT) elevation. The model was developed in 6,949 patients with CHB from a Korean hospital-based cohort, and was validated externally among 7,429 patients with CHB combined from the Taiwanese cohort and seven cohorts from Korea and Hong Kong.

The researchers found that the derivation and validation cohorts identified 435 and 467 incident HCC cases over 10 and 12 years, respectively. One of the strongest predictors of HCC development was baseline hepatitis B virus DNA level, which demonstrated a nonlinear parabolic association in both cohorts, with the highest risk seen for moderate viral loads. Age, sex, platelet count, ALT levels, and positive hepatitis B e antigen result were additional predictors included in the new model. Satisfactory discrimination and calibration were exhibited by the model, with c-statistics of 0.844 and 0.813 in the derivation and validation cohorts, respectively, with multiple imputation. Greater positive net benefit was yielded in the model compared with other strategies in the 0 to 18 percent threshold.

"This model has the potential to inform optimal medical management strategies for patients with CHB who do not meet the current criteria for antiviral treatment," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-09-18 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords